What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Oliver W. Press spends much of his time researching Internal medicine, Surgery, Lymphoma, Radioimmunotherapy and Monoclonal antibody.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Oncology and Tositumomab.
His studies deal with areas such as Total body irradiation and Cyclophosphamide as well as Gastroenterology.
His Lymphoma research incorporates themes from Ibritumomab tiuxetan and Clinical trial.
His Radioimmunotherapy study incorporates themes from Nuclear medicine and Biodistribution.
The various areas that Oliver W. Press examines in his Monoclonal antibody study include Cancer cell, Molecular biology, B cell and Antigen.
His most cited work include:
- Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support (646 citations)
- Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies (579 citations)
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. (570 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Radioimmunotherapy, Oncology, Lymphoma and Surgery.
As part of his studies on Internal medicine, Oliver W. Press frequently links adjacent subjects like Gastroenterology.
The concepts of his Radioimmunotherapy study are interwoven with issues in Cancer research, Nuclear medicine and Biodistribution.
His study in Oncology is interdisciplinary in nature, drawing from both Chemotherapy regimen, Tositumomab, CHOP, Regimen and Mantle cell lymphoma.
His Lymphoma research integrates issues from Clinical trial and Radiation therapy.
His studies in Transplantation integrate themes in fields like B-cell lymphoma, Total body irradiation, Leukemia and Bone marrow.
He most often published in these fields:
- Internal medicine (75.29%)
- Radioimmunotherapy (48.75%)
- Oncology (46.24%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (75.29%)
- Oncology (46.24%)
- Radioimmunotherapy (48.75%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Radioimmunotherapy, Lymphoma and Transplantation.
The study incorporates disciplines such as Gastroenterology and Surgery in addition to Internal medicine.
Oliver W. Press interconnects Regimen, Mantle cell lymphoma, Diffuse large B-cell lymphoma, B-cell lymphoma and Autologous transplantation in the investigation of issues within Oncology.
His Radioimmunotherapy research is multidisciplinary, incorporating perspectives in Cancer research and Toxicity.
His Lymphoma research includes themes of Cancer and Clinical trial.
His Transplantation research includes elements of Haematopoiesis and Multiple myeloma.
Between 2015 and 2021, his most popular works were:
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. (187 citations)
- US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816 (151 citations)
- US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816 (151 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Oliver W. Press focuses on Internal medicine, Lymphoma, Oncology, Cancer research and Gastroenterology.
His work in Internal medicine tackles topics such as Surgery which are related to areas like Hazard ratio.
The concepts of his Lymphoma study are interwoven with issues in Cancer, Radiation therapy and BCL6.
The Oncology study combines topics in areas such as Gene rearrangement, Clinical trial and Chronic lymphocytic leukemia.
His Cancer research study combines topics from a wide range of disciplines, such as Immunology, Immunogenicity, B cell, Pretargeted Radioimmunotherapy and CD20.
His research is interdisciplinary, bridging the disciplines of Chemotherapy and Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
